EGFR and neoplasm: Anti-EGFR nanobodies anchored on extracellular vesicles via glycosyl phosphatidylinositol may improve the targeting ability of extracellular vesicles, highlighting the potential applications of these extracellular vesicles as a drug delivery system and new tool in EGFR-expressing tumor cells (111).